12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mavoglurant regulatory update

The European Commission granted Orphan Drug designation to Novartis' mavoglurant to treat fragile X...

Read the full 46 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >